ReproCELL Incorporated (4978.T)
JPY 103.0
(0.0%)
JPY 103.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.51 Billion JPY | 1.1% |
| 2022 | 1.49 Billion JPY | 3.23% |
| 2021 | 1.45 Billion JPY | -5.24% |
| 2020 | 1.53 Billion JPY | 10.63% |
| 2019 | 1.38 Billion JPY | 8.3% |
| 2018 | 1.27 Billion JPY | -9.2% |
| 2017 | 1.4 Billion JPY | -7.46% |
| 2016 | 1.52 Billion JPY | -2.38% |
| 2015 | 1.55 Billion JPY | 53.18% |
| 2014 | 1.01 Billion JPY | 191.0% |
| 2013 | 349.38 Million JPY | 29.93% |
| 2012 | 268.9 Million JPY | 4.59% |
| 2011 | 257.1 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 442 Million JPY | 6.35% |
| 2023 Q1 | 353 Million JPY | -15.14% |
| 2023 FY | 1.51 Billion JPY | 1.1% |
| 2023 Q4 | 415.6 Million JPY | 11.25% |
| 2023 Q3 | 373.57 Million JPY | -3.57% |
| 2023 Q2 | 387.4 Million JPY | 9.75% |
| 2022 Q1 | 347.85 Million JPY | 2.19% |
| 2022 FY | 1.49 Billion JPY | 3.23% |
| 2022 Q4 | 415.97 Million JPY | 11.86% |
| 2022 Q3 | 371.88 Million JPY | 2.8% |
| 2022 Q2 | 361.76 Million JPY | 4.0% |
| 2021 FY | 1.45 Billion JPY | -5.24% |
| 2021 Q4 | 340.4 Million JPY | -5.72% |
| 2021 Q3 | 361.05 Million JPY | 10.14% |
| 2021 Q2 | 327.82 Million JPY | -22.18% |
| 2021 Q1 | 421.27 Million JPY | 9.7% |
| 2020 Q2 | 408.4 Million JPY | 23.98% |
| 2020 FY | 1.53 Billion JPY | 10.63% |
| 2020 Q1 | 329.42 Million JPY | -18.21% |
| 2020 Q3 | 408.87 Million JPY | 0.12% |
| 2020 Q4 | 384.04 Million JPY | -6.07% |
| 2019 Q3 | 317.01 Million JPY | -4.53% |
| 2019 FY | 1.38 Billion JPY | 8.3% |
| 2019 Q4 | 402.77 Million JPY | 27.05% |
| 2019 Q1 | 331.78 Million JPY | 1.47% |
| 2019 Q2 | 332.06 Million JPY | 0.08% |
| 2018 FY | 1.27 Billion JPY | -9.2% |
| 2018 Q4 | 326.99 Million JPY | 7.92% |
| 2018 Q3 | 302.99 Million JPY | -4.65% |
| 2018 Q2 | 317.78 Million JPY | -3.64% |
| 2018 Q1 | 329.8 Million JPY | -9.69% |
| 2017 Q1 | 361.2 Million JPY | -30.12% |
| 2017 Q4 | 365.18 Million JPY | 10.34% |
| 2017 Q3 | 330.96 Million JPY | -5.34% |
| 2017 Q2 | 349.63 Million JPY | -3.2% |
| 2017 FY | 1.4 Billion JPY | -7.46% |
| 2016 Q1 | 361.87 Million JPY | -18.59% |
| 2016 FY | 1.52 Billion JPY | -2.38% |
| 2016 Q4 | 516.9 Million JPY | 64.41% |
| 2016 Q3 | 314.39 Million JPY | -3.91% |
| 2016 Q2 | 327.19 Million JPY | -9.58% |
| 2015 Q3 | 387.79 Million JPY | 7.31% |
| 2015 Q2 | 361.37 Million JPY | -0.63% |
| 2015 Q1 | 363.67 Million JPY | -17.93% |
| 2015 Q4 | 444.52 Million JPY | 14.63% |
| 2015 FY | 1.55 Billion JPY | 53.18% |
| 2014 Q1 | 116.05 Million JPY | 15.87% |
| 2014 Q4 | 443.11 Million JPY | 56.49% |
| 2014 Q3 | 283.16 Million JPY | 62.39% |
| 2014 Q2 | 174.37 Million JPY | 50.25% |
| 2014 FY | 1.01 Billion JPY | 191.0% |
| 2013 FY | 349.38 Million JPY | 29.93% |
| 2013 Q3 | 101.54 Million JPY | 21.68% |
| 2013 Q1 | 64.22 Million JPY | 0.0% |
| 2013 Q2 | 83.45 Million JPY | 29.94% |
| 2013 Q4 | 100.15 Million JPY | -1.37% |
| 2012 FY | 268.9 Million JPY | 4.59% |
| 2011 FY | 257.1 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -17.871% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -162.478% |
| GNI Group Ltd. | 9.32 Billion JPY | 83.759% |
| Linical Co., Ltd. | 2.7 Billion JPY | 44.033% |
| Trans Genic Inc. | 2.15 Billion JPY | 29.901% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -1.533% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 50.701% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 18.469% |
| AnGes, Inc. | 8.9 Billion JPY | 82.993% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -60.539% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 92.11% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -266.598% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -55.225% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 41.033% |
| CanBas Co., Ltd. | 278 Million JPY | -444.61% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -32.63% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 16.719% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 5.596% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 36.227% |
| PeptiDream Inc. | 9.68 Billion JPY | 84.371% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 22.778% |
| Ribomic Inc. | 1.1 Billion JPY | -36.929% |
| SanBio Company Limited | 4.53 Billion JPY | 66.644% |
| Healios K.K. | 3.48 Billion JPY | 56.581% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -31.113% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -13.455% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -7.877% |
| StemRIM | 2.07 Billion JPY | 27.071% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 22.892% |
| FunPep Company Limited | 313.82 Million JPY | -382.445% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -58.037% |
| Stella Pharma Corporation | 963.98 Million JPY | -57.058% |
| TMS Co., Ltd. | 943.25 Million JPY | -60.51% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -38.907% |
| Cuorips Inc. | 598.11 Million JPY | -153.13% |
| K Pharma,Inc. | 543.94 Million JPY | -178.341% |
| Takara Bio Inc. | 23.9 Billion JPY | 93.667% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -27.874% |
| StemCell Institute Inc. | 1.16 Billion JPY | -30.28% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 0.543% |
| CellSeed Inc. | 804.93 Million JPY | -88.093% |